Public Health Agency of Canada
www.publichealth.gc.ca
Common menu bar links
Institutional links
Diseases & Conditions
Health & Safety
Research & Statistics
Agency Information
Search Box
E-mail this page
HIV-1 Strain and Primary Drug Resistance in Canada
Surveillance Report to June 30, 2002
[Previous] [Table of Contents]
Appendix 2
List of major mutations used for this report1 and corresponding antiretroviral drugs
| Major mutations associated with nucleoside reverse transcriptase inhibitors |
|
|
Mutation2 |
Antiretroviral drugs3 |
|
M41L K65R D67N T69D K70R L74V Y115F Q151M M1841 M184V L210W T215F T215Y K219E K219Q |
AZT, d4T ddC, ddI, Tenofovir, Abacavir AZT, d4T ddC AZT, d4T ddI, ddC, Abacavir Abacavir AZT, ddC, ddI, d4T Abacavir 3TC 3TC, ddC AZT, d4T AZT, d4T AZT, d4T AZT, d4T AZT, d4T |
|
2 Major mutations that have been added to the consensus list since the last surveillance report of samples received as of June 30, 2001, are indicated in bold italics. 3 Other common names for the nucleoside reverse transcriptase inhibitors include AZT (zidovudine, retrovir); d4T (stavudine, zerit); ddC (zalcitabine, hivid); 3TC (lamivudine); ddI (didanosine videx); abacavir (ziagen); tenofovir (viread). |
|
| Major mutations associated with non-nucleoside reverse transcriptase inhibitors |
|
|
Mutation1 |
Antiretroviral drugs2 |
|
L1001 K103N V106A V108I Y181C Y181I Y188C Y188H Y188L G190A G190S P225H M230l P236L |
DLV, NVP, EFV DLV, NVP, EFV NVP NVP, EFV NVP, EFV, DLV NVP, EFV NVP NVP DLV, NVP, EFV NVP, EFV EFV EFV NVP, EFV, DLV DLV |
|
1 Major mutations that have been added to the consensus list since the last surveillance report of samples received as of June 30, 2001, are indicated in bold italics. 2 Other common names for the nucleoside reverse transcriptase inhibitors include efavirenz (sustiva); DLV (delavirdine, rescriptor); NVP (nevirapine, viramune). |
|
| Major mutations associated with resistance to protease inhibitors |
|
|
Mutation1 |
Antiretroviral drugs2 |
|
D30N M461 M46L G48V 150V 150L V82A V82F V82S V82T 184V N88D L90M |
nelfinavir indinavir indinavir saquinavir amprenavir atazanavir indinavir, ritonavir indinavir, ritonavir ritonavir indinavir, ritonavir amprenavir, indinavir, ritonavir nelfinavir nelfinavir, saquinavir |
|
1 Major mutations that have been added to the consensus list since the last surveillance report of samples received as of June 30, 2001, are indicated in bold italics. 2 Other common names for the protease inhibitors include amprenavir (agenarase); indinavirs (crixivan); ritonavir (norvir); saquinavir (invirase, fortovase). |
|
| Major mutations associated with resistance to protease inhibitors |
|
|
Mutation1 |
Antiretroviral drugs2 |
|
D30N M461 M46L G48V 150V 150L V82A V82F V82S V82T 184V N88D L90M |
nelfinavir indinavir indinavir saquinavir amprenavir atazanavir indinavir, ritonavir indinavir, ritonavir ritonavir indinavir, ritonavir amprenavir, indinavir, ritonavir nelfinavir nelfinavir, saquinavir |
|
1 Major mutations that have been added to the consensus list since the last surveillance report of samples received as of June 30, 2001, are indicated in bold italics. 2 Other common names for the protease inhibitors include amprenavir (agenarase); indinavirs (crixivan); ritonavir (norvir); saquinavir (invirase, fortovase). |
|
1 Note: The correlation of drug resistance to genotype in this report is based on scientific consensus of major mutations associated with HIV resistance to antiretroviral drugs as of June 2002. These correlations do not necessarily imply phenotypic resistance to a particular antiretroviral drug in a clinical setting.
